TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 5, 2007, Pages 322-326

  Krayenbuehl, P A ^a   Wiesli, P ^a   Schmid, M ^a   Schmid, C ^a   Ehses, J A ^a   Hersberger, M ^b   Vetter, W ^a   Schulthess, G ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Aspirin; Cardiovascular events; Diabetes mellitus; Hs C reactive protein; Hs CRP; TNF alpha

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CYTOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA POLYMORPHISM; DOSE RESPONSE; GENETIC POLYMORPHISM; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; VASCULAR DISEASE;

AGED; ASPIRIN; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GENE FREQUENCY; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249943626     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-960493     Document Type: Article

References (54)

1. Abraham LJ, Kroeger KM: Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 1999; 66: 562-566
2. Albertini JP, Valensi P, Lormeau B, Aurousseau MH, Ferriere F, Attali JR, Gattegno L: Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes. Care 1998; 21: 1008-1013
3. Altarescu G, Zimran A, Michelakakis H, Etstein D: levels and TNF-alpha gene polymorphism in type I Gaucher disease. Cytokine 2005; 31: 149-152
4. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
5. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forester JS: Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990; 65: 297-302
6. Ceriello A, Motz E: Prevention of vascular events in diabetes mellitus: which "antithrombotic" therapy? Diabetologia 1996; 39: 1405-1406
7. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL: Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes. Diabetes 2005; 54: 97-107
8. Colwell JA, Nesto RW: The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003; 26: 2181-2188
9. Colwell JA: Aspirin therapy in diabetes. Diabetes Care 2004; 27 (Suppl 1):S72-73
10. Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffery S, Kaski JC, Cumberland DC, Duff GW, Crossman DC: Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999; 99: 861-866
11. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454
12. Gao J, Shan G, Sun B, Thompson PJ, Gao X: Association between polymorphism of tumour necrosis factor {alpha}-308 gene promoter and asthma: a meta-analysis. Thorax 2006; 61: 466-471
13. Gonzalez S, Rodrigo L, Martinez-Borra J, Lopez-Vazquez A, Fuentes D, Nino P, Cadahia V, Saw C, Dieguez MA, Lopez-Larrea C: TNF-alpha - 308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease. Am J Gastroenterol 2003; 98: 1101-1106
14. Gordon MA, Oppenheim E, Camp NJ, di Giovine FS, Duff GW, Gleeson D: Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. J Hepatol 1999; 31: 242-247
15. Haffner SM: Coronary heart disease in patients with diabetes. N Engl J Med 2000; 342: 1040-1042
16. Hajeer AH, Hutchinson IV: Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 2001; 62: 1191-1199
17. Hanjis C, Frishman WH, Lerner RG: Aspirin resistance: mechanisms and clinical implications. Cardiol Rev 2006; 14: 18-25
18. Hansson GK, Jonasson L, Seifert PS, Stemme S: Immune mechanisms in atherosclerosis. Arteriosclerosis 1989; 9: 567-578
19. Herrmann SM, Ricard S, Nicaud V, Mallet C, Arveiler D, Evans A, Ruidavets JB, Luc G, Bara L, Parra HJ, Poirier O, Cambien F: Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest 1998; 28: 59-66
20. Jones DE, Watt FE, Grove J, Newton JL, Daly AK, Gregory WL, Day CP, James OF, Bassendine MF: Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J Hepatol 1999; 30: 232-236
21. Kaartinen M, Penttilä A, Kovanen PT: Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-α. Circulation 1996; 94: 2787-2792
22. Kallas EG, Reynolds K, Andrews J, Treanor JJ, Evans TG: Production of influenza-stimulated tumor necrosis factor-alpha by monocytes following acute influenza infection in humans. J Interferon Cytokine Res 1999; 19: 751-755
23. Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP: In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat Genet 2003; 33: 469-475
24. Knopp RH, Retzlaff B, Aikawa K, Kahn SE: Management of patients with diabetic hyperlipidemia. Am J Cardiol 2003; 91 (7A):24E-28E
25. Koch W, Kastrati A, Bottiger C, Mehilli J, von Beckerath N, Schomig A: Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 2001; 159: 137-144
26. Krayenbuehl P, Maly FE, Hersberger M, Wiesli P, Himmelmann A, Eid K, Greminger P, Vetter W, Schulthess G: Tumor Necrosis Factor-α-308G>A polymorphism modulates iron accumulation in patients with hereditary hemochromatosis. Clin Chem 2006; 52: 1552-1558
27. Krikovszky D, Vasarhelyi B, Toth-Heyn P, Korner A, Tulassay T, Madacsy L: Association between -308G>A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. Clin Genet 2002; 62: 474-477
28. Kristiansen OP, Mandrup-Poulsen T: Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 2005; 54 (Suppl 2):S114-124
29. Kroeger KM, Carville KS, Abraham LJ: The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997; 34: 391-399
30. Kutuk O, Basaga H: Aspirin inhibits TNFalpha- and IL-1-induced NF-kappaB activation and sensitizes HeLa cells to apoptosis. Cytokine 2004; 25: 229-237
31. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-2850
32. Majetschak M, Obertacke U, Schade FU, Bardenheuer M, Voggenreiter G, Bloemeke B, Heesen M: Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients. Clin Diagn Lab Immunol 2002; 9: 1205-1211
33. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R: Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005; 28: 690-693
34. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D: Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371: 508-510
35. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riche F, Leleu C, Arbibe L, Mignon A, Delpech M, Dhainaut JF: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282: 561-568
36. Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama S: Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients. Diabetes 1997; 46: 2096-2101
37. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB: Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599-2610
38. Plutzky J: Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001; 88 (suppl):10K-15K
39. Roberts WL: CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: laboratory tests available to assess inflammation-performance and standardization: a background paper. Circulation 2004; 110: e572-576
40. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group.: Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264-3272
41. Schaaf BM, Boehmke F, Esnaashari H, Seitzer U, Kothe H, Maass M, Zabel P, Dalhoff K: Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med 2003; 168: 476-480
42. Schiekofer S, Franke S, Andrassy M, Chen J, Rudofsky G, Schneider JG, von Eynatten M, Wendt T, Morcos M, Kientsch-Engel R, Stein G, Schleicher E, Nawroth PP, Bierhaus A: Postprandial mononuclear NF-kappaB activation is independent of the AGE-content of a single meal. Exp Clin Endocrinol Diabetes 2006; 114: 160-167
43. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB: C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004; 27: 889-894
44. Shin HD, Park BL, Kim LH, Jung JH, Wang HJ, Kim YJ et al: Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. Hum Mol Genet 2004; 13: 397-403
45. Sookoian S, Garcia SI, Gianotti TF, Dieuzeide G, Gonzalez CD, Pirola CJ: The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with hypertension in adolescents harboring the metabolic syndrome. Am J Hypertens 2005; 18: 1271-1275
46. Staiger H, Häring HU: Adipocytokines: Fat-derived humoral mediators of metabolic homeostasis. Exp Clin Endocrinol Diabetes 2005; 113: 67-79
47. Tsiavou A, Hatziagelaki E, Chaidaroglou A, Manginas A, Koniavitou K, Degiannis D, Raptis A: TNF-α, TGF-β, IL-6, gene polymorphisms in latent autoimmune diabetes of adults and type 2 diabetes mellitus. J Clin Immunol 2004; 24: 591-599
48. Vatay A, Rajczy K, Pozsonyi E, Hosszufalusi N, Prohaska Z, Füst G, Karadi I, Szalai C, Grosz A, Bartfai Z, Panczel P: Differences in the genetic backgroud of latent autoimmune diabetes in adults and type 1 diabetes mellitus. Immunol Lett 2002; 84: 109-115
49. Vendrell J, Fernandez-Real JM, Gutierrez C, Zamora A, Simon I, Bardaji A, Ricart W, Richart C: A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis 2003; 167: 257-264
50. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-3199
51. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone F, Tanaka M, Yokota M: Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347: 1916-1923
52. Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)-beta. Nature 1988; 396: 77-80
53. Zeggini E, Groves CJ, Parkinson JR, Halford S, Oven KR, Frayling TM et al: Large-scale studies of the association between variations at the TNF/LTA locus and susceptibility to type 2 diabetes. Diabetologica 2005; 48: 2013-2017
54. Zipperlen K, Peddle L, Melay B, Hefferton D, Rahman P: Association of TNF-alpha polymorphisms in Crohn disease. Hum Immunol 2005; 66: 56-59